Clinical Trials

652 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06943872 2026-03-04

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

630 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07132684 2026-03-02

Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients

240 enrolled

Phase 3 Not yet recruiting

Leukemia, Myeloid, Acute

NCT07407140 2026-03-02

VAG-3+7-G

300 enrolled

Leukemia, Myeloid, Acute

NCT05057494 2026-02-18

MAJIC

607 enrolled

Phase 3 Not yet recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07407660 2026-02-12

Shortened Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in Elderly or Frail Patients With AML Patients Treated With Azacitidine Plus Venetoclax

250 enrolled

Leukemia, Myeloid, Acute

NCT03768063 2026-01-29

IMbrella B

1,000 enrolled

Tumor-Agnostic

Neoplasms

NCT04965493 2026-01-29

BRUIN CLL-322

600 enrolled

Hematologic Diseases, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT03926624 2026-01-22

Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

167 enrolled

Leukemia, Myeloid, Acute

NCT06852222 2026-01-16

cAMeLot-2

600 enrolled

Leukemia, Myeloid, Acute

NCT02242942 2025-11-06

Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

445 enrolled 22 charts 1 FDA

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06428019 2025-11-05

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

170 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04161885 2025-10-06

VIALE-T

465 enrolled

Neoplasms, Leukemia, Myeloid, Acute

NCT04229979 2025-10-01

REGAL

127 enrolled

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT03069352 2025-09-30

A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

211 enrolled 30 charts 2 FDA

Leukemia, Leukemia, Myeloid, Acute

NCT07152041 2025-09-03

CAMS-Ph+ B-ALL

150 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04102020 2025-08-20

VIALE-M

112 enrolled 13 charts

Leukemia, Myeloid, Acute

NCT02993523 2025-08-19

Viale-a

443 enrolled 14 charts 2 FDA

Leukemia, Myeloid, Acute

NCT06990321 2025-08-08

Effectiveness of Medium-Dose Cytarabine Combined With Venetoclax for Consolidation Therapy in Elderly Patients With Intermediate to High-Risk Acute Myeloid Leukemia

68 enrolled

Leukemia, Myeloid, Acute

NCT03112174 2025-07-22

SYMPATICO

366 enrolled 45 charts

Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT03539744 2025-06-19

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

265 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Recurrence

NCT05079230 2025-04-04

ENHANCE-3

378 enrolled 29 charts

Leukemia, Myeloid, Acute

NCT04778397 2025-02-05

ENHANCE-2

258 enrolled 25 charts

Leukemia, Myeloid, Acute

NCT04608318 2024-12-31

CLL17

897 enrolled

Leukemia, B-Cell

NCT02950051 2024-12-30

GAIA

926 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03836261 2024-12-27

AMPLIFY

984 enrolled 1 FDA

Leukemia, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03406156 2024-08-06

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

120 enrolled 14 charts

Chromosome 17 deletion, Neoplasms, Tumor Lysis Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell

NCT06496308 2024-07-11

Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment

78 enrolled

Lymphoid

Lymphoma, Mantle-Cell

NCT02005471 2023-10-17

MURANO

389 enrolled 35 charts 2 FDA

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06073730 2023-10-10

Viale-a

Phase 3 Unknown

154 enrolled

Leukemia, Myeloid, Acute

NCT02755597 2023-08-22

Bellini

291 enrolled 24 charts

Plasma cell

Multiple Myeloma

NCT03941964 2023-03-20

A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy

60 enrolled 12 charts

Neoplasms, Leukemia, Myeloid, Acute

NCT02980731 2023-02-22

VENICE II

210 enrolled 36 charts

Chromosome 17 deletion, Leukemia, Lymphocytic, Chronic, B-Cell

NCT05654194 2022-12-16

Azacitidine Combined With Venetoclax and ATRA in Newly Diagnosed AML

Phase 3 Unknown

30 enrolled

Leukemia, Myeloid, Acute

NCT04509622 2022-05-05

A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML)

14 enrolled